BlackRock, Inc. 13D and 13G filings for Iovance Biotherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-01-26 11:49 am Purchase |
2023-12-31 | 13G | Iovance Biotherapeutics, Inc. IOVA |
BlackRock Inc. BLK |
19,071,756 7.500% |
6,995,480 (+57.93%) |
Filing |
| 2023-02-03 12:10 pm Purchase |
2022-12-31 | 13G | Iovance Biotherapeutics, Inc. IOVA |
BlackRock Inc. BLK |
12,076,276 7.700% |
4,667,771 (+63.01%) |
Filing |
| 2022-02-24 5:23 pm Sale |
2021-12-31 | 13G | Iovance Biotherapeutics, Inc. IOVA |
BlackRock Inc. BLK |
7,408,505 4.700% |
-1,594,083 (-17.71%) |
Filing |
| 2021-01-29 09:57 am Sale |
2020-12-31 | 13G | Iovance Biotherapeutics, Inc. IOVA |
BlackRock Inc. BLK |
9,002,588 6.100% |
-592,072 (-6.17%) |
Filing |